Show simple item record

dc.contributor.authorShanmugam, M.
dc.contributor.authorKumar, Alan Prem
dc.contributor.authorTan, B.
dc.contributor.authorSethi, G.
dc.date.accessioned2017-06-23T02:58:59Z
dc.date.available2017-06-23T02:58:59Z
dc.date.created2017-06-19T03:39:39Z
dc.date.issued2013
dc.identifier.citationShanmugam, M. and Kumar, A.P. and Tan, B. and Sethi, G. 2013. Role of NF-κB in tumorigenesis. Forum on Immunopathological Diseases and Therapeutics. 4 (2): pp. 181-196.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/53174
dc.identifier.doi10.1615/ForumImmunDisTher.2013008382
dc.description.abstract

Persistent activation of the pro-inflammatory transcription factor nuclear factor-κB (NF-κB) is frequently observed in several human malignancies and can drive the processes of tumor initiation, oncogenic transformation, and malignant progression. Once activated, this master transcription factor regulates the expression of numerous genes involved in proliferation, survival, metastasis, angiogenesis, chemoresistance, and radioresistance. Thus, novel pharmacological agents that can suppress constitutive and/or inducible NF-κB activation have the potential for cancer therapy. In this review, we describe in detail the pleiotropic molecular mechanisms of aberrant NF-κB activation and also discuss various therapeutic strategies employed to suppress deregulated activation of this important oncogenic transcription factor in cancer.

dc.titleRole of NF-κB in tumorigenesis
dc.typeJournal Article
dcterms.source.volume4
dcterms.source.number2
dcterms.source.startPage181
dcterms.source.endPage196
dcterms.source.issn2151-8017
dcterms.source.titleForum on Immunopathological Diseases and Therapeutics
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record